Nelly Kuklin, Ph.D.
Senior Vice President of Discovery Biology & Translational Science
Nelly Kuklin, Ph.D., joined Nirogy Therapeutics in April 2022, bringing over 20 years of scientific, strategic, and operational leadership experience advancing programs from early-stage discovery through clinical development in the in multiple disease areas. Prior to Nirogy, Nelly was a Vice President at Compass Therapeutics where she directed early and late-stage pipeline in Immuno-oncology and autoimmunity. At Gemini Therapeutics and at Alexion Pharmaceuticals Nelly successfully advanced complement related rare disease programs and directed biomarker strategy for a large company drug portfolio.
Nelly has 14 years tenure track at Merck Research Laboratories where she advanced from senior immunologist to a director position. As a pharmacology department head, he led groups of more than 17 scientists and technical personnel. At Merck, Nelly was a key contributor and a successful leader of multiple programs including IgF1R mAb program in oncology, Staphylococcus vaccine program, Human Papilloma Virus vaccine (Gardasil) from early discovery to clinical trials and to market.
Nelly holds a Ph.D. in Viral Immunology from University of Tennessee Knoxville and post-doctoral training in Immunology at Stanford University. She is an author of over 40 peer reviewed publications and patents.